{"organizations": [], "uuid": "e363e4b4570060705ef1a5950293225ba865273d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-plan/brief-tenax-therapeutics-announces-plan-to-develop-levosimendan-for-a-pulmonary-hypertension-indication-with-no-fda-approved-therapies-idUSFWN1PB0TO", "country": "US", "domain_rank": 408, "title": "BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-16T14:57:00.000+02:00", "replies_count": 0, "uuid": "e363e4b4570060705ef1a5950293225ba865273d"}, "author": "", "url": "https://www.reuters.com/article/brief-tenax-therapeutics-announces-plan/brief-tenax-therapeutics-announces-plan-to-develop-levosimendan-for-a-pulmonary-hypertension-indication-with-no-fda-approved-therapies-idUSFWN1PB0TO", "ord_in_thread": 0, "title": "BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda approved therapies reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "tenax therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 57 PM / Updated 5 minutes ago BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies Reuters Staff 1 Min Read \nJan 16 (Reuters) - Tenax Therapeutics Inc: \n* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES \n* TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION \n* TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018 \n* TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-16T14:57:00.000+02:00", "crawled": "2018-01-16T15:12:27.001+02:00", "highlightTitle": ""}